Tiny Health, Pioneer of the First At-Home Baby Gut Microbiome Test, Aims to Address the Pediatric Chronic Conditions Crisis
March 05, 2024 09:00 ET
|
Tiny Health
AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Tiny Health, the first at-home gut microbiome test developed for babies, today announced a $8.5 million Series A round led by Spero Ventures,...
Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging
February 23, 2024 11:12 ET
|
The Wistar Institute
PHILADELPHIA, PA, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The Wistar Institute’s associate professor Mohamed Abdel-Mohsen, Ph.D., has demonstrated, with his lab and collaborators, a connection between...
Human Microbiome Market to hit USD 6.5 billion by 2032, says Global Market Insights Inc.
October 31, 2023 07:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Human Microbiome Market size will be worth over USD 6.5 billion by 2032. In the current era of scientific advancement, understanding the...
For The Biome Delivers Highly Anticipated Formulation of Cistus Incanus to North American Market, Mediterranean Herb Clinically Proven to Strengthen Immune Response in 2 Hours
March 30, 2021 08:50 ET
|
For The Biome
DUMMERSTON, VT, March 30, 2021 (GLOBE NEWSWIRE) -- For The Biome, founded by industry innovator and master herbalist Paul Schulick, has launched Immune Therapy Cistus+ Infusion, a groundbreaking...
Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.
May 22, 2020 12:35 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 22, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger transaction...
Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC
April 16, 2020 14:07 ET
|
Ritter Pharmaceuticals, Inc.
Special Meeting of Ritter Pharmaceuticals, Inc. Stockholders to Vote on Proposed Merger Scheduled for May 14, 2020 LOS ANGELES , April 16, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc....
Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019
March 31, 2020 17:27 ET
|
Ritter Pharmaceuticals, Inc.
Definitive merger agreement with Qualigen, Inc. announced in January 2020 LOS ANGELES, March 31, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”,...
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
January 21, 2020 09:15 ET
|
Ritter Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...
Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update
November 13, 2019 19:35 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...
Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
June 27, 2018 07:05 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...